{"id":"bl-m07d1","safety":{"commonSideEffects":[{"rate":null,"effect":"Adverse event 1"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of BL-M07D1 is not well understood, but it is believed to work by interacting with the molecular target, leading to a specific therapeutic effect.","oneSentence":"BL-M07D1 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:30.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication 1"}]},"trialDetails":[{"nctId":"NCT06293898","phase":"PHASE1","title":"Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors","status":"RECRUITING","sponsor":"SystImmune Inc.","startDate":"2024-02-09","conditions":"Endometrial Cancer, Cervical Cancer, Ovarian Cancer","enrollment":280},{"nctId":"NCT07264816","phase":"PHASE2","title":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2026-02-03","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT06830889","phase":"PHASE3","title":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-03","conditions":"HER2-positive Breast Cancer","enrollment":1450},{"nctId":"NCT06957886","phase":"PHASE3","title":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-05-15","conditions":"HER2-low Breast Cancer","enrollment":566},{"nctId":"NCT07178795","phase":"PHASE3","title":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-09-29","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":440},{"nctId":"NCT07152405","phase":"PHASE3","title":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-09-24","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":490},{"nctId":"NCT06891833","phase":"PHASE2, PHASE3","title":"A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-05","conditions":"HER2-positive Breast Cancer","enrollment":120},{"nctId":"NCT06131450","phase":"PHASE1, PHASE2","title":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-02-29","conditions":"Gynecological Malignancies","enrollment":138},{"nctId":"NCT05631964","phase":"PHASE1","title":"Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-01-05","conditions":"Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors","enrollment":26},{"nctId":"NCT05461768","phase":"PHASE1","title":"A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-08-09","conditions":"Breast Cancer, Locally Advanced or Metastatic Solid Tumor","enrollment":26},{"nctId":"NCT06316531","phase":"PHASE3","title":"A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-05-08","conditions":"HER2-positive Breast Cancer","enrollment":274},{"nctId":"NCT06423885","phase":"PHASE2","title":"A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-12-24","conditions":"HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT06031584","phase":"PHASE1, PHASE2","title":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-01-19","conditions":"Her2-positive/Low-expression Urinary and Digestive Tract Tumors","enrollment":42},{"nctId":"NCT06445400","phase":"PHASE2","title":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-19","conditions":"HER2-positive Breast Cancer","enrollment":120},{"nctId":"NCT06114511","phase":"PHASE1, PHASE2","title":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-04-24","conditions":"Non-small Cell Lung Cancer","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BL-M07D1","genericName":"BL-M07D1","companyName":"Sichuan Baili Pharmaceutical Co., Ltd.","companyId":"sichuan-baili-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BL-M07D1 is a small molecule drug that targets the molecular target. Used for Indication 1.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}